Introduction
The adult mammalian central nervous system (CNS) has an extremely limited capacity to regenerate axons following injury [7, 31, 43] . The reduced regenerative ability is attributable to the progressive disappearance of growth-promoting factors or the increasing appearance of growth-inhibitory molecules during maturation of the CNS. A growing body of evidence shows that CNS myelin and oligodendrocytes represent a non-permissive substrate for neurite outgrowth [41, 42] . Previously, two myelin membrane-associated proteins of 35 kDa and 250 kDa, presenting with a potent inhibitory activity on neurite outgrowth in vitro, were purified biochemically from the CNS white matter, and they were designated NI-35 and NI-250, respectively [13] . Neutralization of these proteins by treatment with a NI-35/250-specific monoclonal antibody (mAb) termed IN-1 promotes long-distance axonal regeneration in the lesioned adult mammalian CNS, accompanied by enhanced functional recovery [10, 12, 47, 49, 50] .
Recently, a novel type-II membrane protein which acts as a regulator of stable and specific neuronal fibre connections was identified as a component of the CNS myelin and designated Nogo [3, 9, 17, 22, 46] . The cloned rat and human Nogo genes encode three distinct transcripts, named Nogo-A, -B and -C, derived by alternative splicing and promoter usage, all of which have a common C-terminal domain that is homologous to the members of reticulon protein family [14, 20, 33] . Nogo-A, the largest transcript encoding an open reading frame of 1192 amino acid, corresponds to NI-250, while an intermediate-length variant, termed Nogo-B, devoid of amino acid residues 186-1004 of Nogo-A, corresponds to NI-35. The shortest variant, termed Nogo-C, with a truncated N-terminal domain, also lacks amino acid residues 186-1004 of Nogo-A. Nogo-A is found to be expressed almost exclusively on oligodendrocytes, where it is chiefly located in the endoplasmic reticulum and the Golgi complex [14] . A topographic model suggests that both N-and C-termini of Nogo-A are located in the cytoplasmic compartment, while a small C-terminal segment composed of 66 amino acid residues positioned between the two putative transmembrane domains (Nogo-66), shared among all three Nogo isoforms, protrudes on the extracellular side of the endoplasmic reticulum or the plasma membrane [20, 22, 46] . Several studies have shown that Nogo-66, by itself, exhibits a strong inhibitory activity on neurite extension of dorsal root ganglion neurones, suggesting that all three Nogo variants could be inhibitory to neurite outgrowth [16, 20] . In contrast, different studies have shown that the main inhibitory domain is located within the N-terminal cytoplasmic region expressed only by Nogo-A, and this domain exhibits its activity when it is released from intracellular stores of injured oligodendrocytes [9, 14, 33] . Recently, a high affinity receptor specific for Nogo-66 (NgR) has been identified [16] . NgR is a 85 kDa protein composed of a signal sequence followed by eight leucine-rich-repeat (LRR) domains, a cysteinerich LRR carboxy-terminal flanking domain and a glycosylphosphatidylinositol anchorage site. Unlike Nogo-A, NgR is undetectable on oligodendrocytes but is expressed chiefly on subpopulations of neurones, including cerebral cortical pyramidal neurones and cerebellar Purkinje cells whose axonal regeneration is enhanced greatly by treatment with IN-1 mAb [16] . These observations suggest that a selective blockade on the interaction between Nogo-66 and NgR might provide a novel therapeutic approach for promoting recovery after injury in the human CNS [10, 12, 47, 49, 50] .
CNS injury is nearly always accompanied by local inflammatory reaction, composed of a breakdown of the blood-brain barrier, an infiltration of lymphocytes and macrophages and an activation of microglia and astrocytes, all of which provide a possible source of reactive oxygen species, proinflammatory cytokines, such as tumour necrosis factor (TNF)-a and interleukin-1 (IL-1), and neurotrophic factors, such as basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF) and glia-derived neurotrophic factor (GDNF) [4, 7, 15, 31, 43] . The receptors specific for these factors have been identified on a wide range of neuronal and glial cell types [19, 29, 45] . A variety of cytokines and neurotrophic factors play a key role in axonal regeneration and survival of specific subsets of neurones at the site of injury in the CNS [7, 15, 31, 43, 48] . The exogeneous application of bFGF, BDNF and GDNF rescues axotomized CNS neurones from retrograde cell death [6, 8, 21, 26] . TNF-a induces the apoptotic cell death of oligodendrocytes [2, 27] , whereas this cytokine, along with IL-1, promotes proliferation of astrocytes, contributing to formation of the scars which inhibit axonal regeneration [18, 44] . Macrophage/microglial lineage cells accelerate regeneration of injured axons not only by removing myelin debris, but also by releasing a broad range of mediators capable of making the neuronal environment supportive of regeneration [28, 40] . Impotantly, neuronal deafferentation signals lead directly or indirectly to an activation of glial cells [43] . Based on these observations, a hypothesis can be proposed that the locally produced cytokines and neurotrophic factors might regulate Nogo and NgR expression in surviving neurones and activated glial cells at post-traumatic inflammatory lesions.
To evaluate this hypothesis, the present study was designed to investigate: (i) the constitutive expression of Nogo and NgR mRNA in human neural cell lines;
(ii) Nogo and NgR mRNA levels in NTera2 human teratocarcinoma cell line during retinoic acid (RA)-induced neuronal differentiation; and (iii) their regulation in NTera2-derived differentiated neurones after exposure to a panel of cytokines and growth factors which are potentially involved in inflammation-related axonal regeneration in the CNS.
Materials and methods

Human neural cell lines
The human neural and non-neural cell lines were obtained from the RIKEN Cell Bank (Tsukuba, Japan) and the American Type Culture Collection (Rockville, MD, USA). They were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml of penicillin and 100 mg/ml of streptomycin (feeding medium). NTera2/c.D1 (NTera2) is a pluripotent human teratocarcinoma-derived clonal cell line [1] . When maintained under standard culture conditions, NTera2 cells exhibit characteristics of undifferentiated neuronal progenitor cells, while they can differentiate after RA treatment into postmitotic neurones which have an extension of neuritic processes containing neurofilament protein triplets and multiple neurotransmitter proteins [32, 34, 36] . For induction of neuronal differentiation, NTera2 teratocarcinoma cells maintained in the undifferentiated state (NTera2-U) were incubated for 4 weeks in the feeding medium containing 10 x5 M of all trans RA (Sigma, St Louis, MO, USA), replated twice and then plated on the surface coated with Matrigel Basement Membrane Matrix (Becton Dickinson, Bedford, MA, USA). They were incubated further for 2 weeks in the feeding medium containing a cocktail of mitotic inhibitors and replated in poly L-lysine-coated culture flasks to establish the differentiated neurone-enriched cultures (NTera2-N) as described previously [34, 36] . For treament with cytokines and neurotrophic factors, NTera2-N cells were incubated for 24 h in the serum-free DMEM/F-12 medium supplemented with insulin, transferrin and selenium (ITS-G; Gibco-BRL, Gaithersburg, MD, USA) (experiment medium). Then, the medium was renewed and the cells were incubated for further 48 h in the experiment medium containing 100 ng/ml of recombinant human bFGF (Sigma), BDNF (Sumitomo Pharmaceutical, Osaka, Japan), GDNF (PeproTech, London, UK), TNF-a (PeproTech) or IL-1b (PeproTech), or 1 mM of dibutyryl cyclic AMP (dbcAMP; Sigma), an activator of protein kinase A, or 100 nM of phorbol 12-myristate 13-acetate (PMA; Sigma), an activator of protein kinase C, followed by processing for RNA preparation.
Reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis
Total RNA was extracted from the cells and tissues by the acid guanidinium thiocyanate-phenol-chloroform method using TRIZOL reagent (Gibco-BRL). DNasetreated RNA samples were processed for cDNA synthesis using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and SuperScript II reverse transcriptase (Gibco-BRL). cDNA was amplified by PCR using a panel of sense and antisense primer sets shown in Table 1 . PCR was carried out in 50 ml of reaction mixture containing Taq DNA polymerase buffer (20 mM Tris-HCl, pH 8.4, 50 mM KCl, 200 mM dNTP, 1.5 mM MgCl 2 , 0.5 mM each primer) and 1.25 U Taq DNA polymerase (Gibco-BRL). The amplification program consisted of a denaturing step at 94uC for 1 min, an annealing step at 60uC for 40 s and an extension step at 72.9uC for 50 s, for 35 cycles except for the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene amplified for 30 cycles. The PCR products separated on a 1.5% agarose gel were transferred onto a nylon membrane. The membranes were hybridized at 60uC overnight with the internal oligonucleotide probe specific for the human Nogo-A or NgR gene (Table 1 ) labelled with digoxigenin (DIG)-11-dUTP by the DIG oligonucleotide tailing kit (Roche Diagnostics, Mannheim, Germany). The specific reaction was visualized by the DIG chemiluminescence detection kit (Roche Diagnositics).
Northern blot analysis
Four mg of total RNA was separated on a 1.5% agarose/ 6% formaldehyde gel and transferred onto a nylon membrane. After prehybridization, the membranes were hybridized at 54uC overnight with the DIG-labelled DNA probe synthesized by the PCR DIG probe synthesis kit (Roche Diagnositics) using the specific primer sets (Table 1) , followed by rehybridization with the DIGlabelled human b-actin antisense RNA probe (Roche Diagnositics) as described previously [35] [36] [37] [38] . The specific reaction was visualized on Kodak X-OMAT AR X-ray films by the DIG chemiluminescence detection kit (Roche Diagnositics). The levels of Nogo, NgR and GAP-43 mRNA were standardized against the corresponding b-actin mRNA signals detected on the identical blots. The densitometric analysis was performed on an imaging system using a NIH image Version 1.61 software (National Institute of Health, Bethesda, MD, USA). The validity of quantification in Northern blot analysis was determined by analysing a standard dose-response reaction ( 
Results
The constitutive expression of Nogo-A and Nogo receptor mRNA in human neural and non-neural cell lines PCR was performed using three different primer sets specific for the human Nogo gene shown in Table 1 . They match the sequence of the central segment specific for the Nogo-A transcript (a 401-bp PCR product; Figure 1a ,b), the sequence of the N-terminal domain shared between Nogo-A and Nogo-B but deleted in Nogo-C (a 260-bp PCR product; Figure 1c ), or the sequence of the C-terminal domain common among all three Nogo transcripts (a 372-bp PCR product; Figure 1d ). The specificity of PCR was verified by Southern blot analysis using the Nogo-A-specific internal oligonucleotide probe (Figure 1b) . By RT-PCR analysis Figure 1 . Nogo-A mRNA expression in human neural and non-neural cell lines. Fifty ng of cDNA was amplified by PCR using three different primer sets listed in Table 1 , directed to the sequence specific for the human Nogo-A transcript (a,b), the sequence shared between Nogo-A and Nogo-B transcripts (c), or the sequence common among all three Nogo transcripts (d). The amplified products separated on a 1.5% agarose gel were transferred onto a nylon membrane and hybridized with the Nogo-A-specific internal oligonucleotide probe (b). Ethidium bromide staining of the gels is shown in (a,c,d), while (b) is a Southern blot of the gel corresponding to (a). Lanes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) represent the following human cells and tissues: (1) IMR-32 neuroblastoma, (2) SK-N-SH neuroblastoma, (3) U-373MG astrocytoma, (4) NTera2 teratocarcinoma maintained in the undifferentiated state (NTera2-U), (5) NTera2-derived differentiated neurones (NTera2-N), (6) HeLa cervical carcinoma, (7) HepG2 hepatoblastoma, (8) cultured skin fibroblasts (SF), (9) peripheral blood mononuclear cells (PBMC), (10) cerebrum processed for PCR including the reverse transcription (RT) step, (11) cerebrum processed for PCR omitting the RT step, (12) cerebellum, (13) peripheral nerve of the cauda equina and (14) skeletal muscle. The DNA size marker (bp) is shown on the left. Nogo-A specific sense 5k-CACATGTGCTCCCTTTAACCCAGC-3k 401 AJ251383 Nogo-A specific antisense 5k-GCTGTGCTGCAGGATAGAGTGACT-3k Nogo-A specific IOL 5k-AATCTGGAGTCAGGCCTTCAGGCA-3k Nogo-A/B shared sense 5k-ATGGAAGACCTGGACCAGTCTCCT-3k 260 AJ251384 Nogo-A/B shared antisense 5k-GGCACGAAGTCATTTCCGAAGTCC-3k Nogo-A/B/C common sense-1 5k-ATGAAGGCCACCCATTCAGGGCAT-3k 372 AJ251385 Nogo-A/B/C common antisense-1 5k-CAGCTTTGCGCTTCAATCCAGGGA-3k Nogo-A/B/C common sense-2 5k-GTTGACCTCCTGTACTGGAGAGAC-3k 559 AJ251385 Nogo-A/B/C common antisense-1 5k-CAGCTTTGCGCTTCAATCCAGGGA-3k NgR sense 5k-CAGTACCTGAGGCTCAACGACAAC-3k 588 AF283463 NgR antisense 5k-ACCTGAGCCTTCTGAGTCACCAGT-3k NgR IOL 5k-AGGGTGAGTCATTGATGTGCCGTG-3k G3PDH sense 5k-CCATGTTCGTCATGGGTGTGAACCA-3k 251 J04038 G3PDH antisense 5k-GCCAGTAGAGGCAGGGATGATGTTC-3k IOL, internal oligonucleotide; NgR, Nogo receptor; G3PDH, glyceraldehyde-3-phosphate dehydrogenase. The Nogo-A-specific primers match the sequence of the central segment of Nogo-A, while the Nogo-A/B shared or the Nogo-A/B/C common primers match the sequence of the N-terminal or the C-terminal domain of Nogo-A, respectively [33] . The primer set of Nogo-A/B/C common sense-1 and antisense-1 was used for PCR analysis of Nogo mRNA expression, while that of Nogo-A/B/C common sense-2 and antisense-1 was applied to synthesis of the DIG-labelled DNA probe for Northern blot analysis.
using three distinct primer sets, Nogo-A mRNA expression was identified in all human neural and non-neural cell lines examined, including IMR-32 neuroblastoma, SK-N-SH neuroblastoma, U-373MG astrocytoma, NTera2 teratocarcinoma maintained in the undifferentiated state (NTera2-U), NTera2-derived differentiated neurones (NTera2-N), HeLa cervical carcinoma and HepG2 hepatoblastoma (Figure 1a-d, lanes 1-7) . The Nogo-A transcript was also expressed in cultured skin fibroblasts, peripheral blood mononuclear cells and adult human tissues of the cerebrum, cerebellum, peripheral nerve and skeletal muscle (Figure 1a-d, lanes 8-10,  12-14) . These results suggest that the full-length of Nogo-A transcript is expressed constitutively in various human neural and non-neural cell lines. By RT-PCR and subsequent Southern blot analysis, variable levels of Nogo receptor (NgR) mRNA expression were identified in all human neural and non-neural cells and tissues examined (a 588-bp PCR product; Figure 2a ,b, lanes 1-10, 12-14). The levels of G3PDH mRNA, a housekeeping gene, were almost constant among the cells and tissues examined (Figure 2c, lanes  1-10, 12-14) . In contrast, no products were amplified when total RNA was processed for PCR without reverse transcription, confirming that a contamination of genomic DNA was excluded (Figures 1 and 2 , all panels, lane 11). These results indicate that NgR mRNA is coexpressed with Nogo-A mRNA in human neural and non-neural cell lines and tissues.
Both Nogo-A and GAP-43 mRNA expression is up-regulated in NTera2 cells during neuronal differentiation
In the next step, Nogo and NgR mRNA expression was studied in NTera2 cells during RA-induced neuronal differentiation by Northern blot analysis using the probe specific for the sequence common among all three human Nogo transcripts, or the probe specific for the human NgR gene. The constitutive expression of Nogo-A (4.6 kb), Nogo-B (2.6 kb) and NgR (2.3 kb) mRNA was identified in NTera2-U cells (Figure 3a,b,  lane 1) . The levels of Nogo-A mRNA were elevated in NTera2 cells after RA-induced neuronal differentiation, with a 2.1-fold increase (SIR 2.1) in NTera2-N cells compared to the level in NTera2-U cells, when standardized against corresponding b-actin mRNA signals detected on the identical blots (Figure 3a,d, lanes 1-7) .
In contrast, Nogo-B and NgR mRNA levels were unaltered in NTera2 cells during RA-induced neuronal differentiation beyond the range of SIR 0.5-2.0 compared to the levels in NTera2-U cells (Figure 3a,b,d,  lanes 1-7) . Nogo-C transcript was barely detectable in both NTera2-U and NTera2-N cells. The levels of GAP-43 mRNA (1.7 kb and 1.5 kb transcripts expressed as a single band), a marker for neurite outgrowth, were elevated in NTera2 cells following RA-induced neuronal differentiation, with a 3.7-fold increase in NTera2-N cells compared to the level in NTera2-U cells, when standardized against corresponding b-actin mRNA signals detected on the identical blots (Figure 3c,d,  lanes 1-7) . These results indicate that Nogo-A mRNA expression is up-regulated in NTera2 cells after neuronal differentiation, associated with an increased expression of GAP-43 mRNA.
Nogo and NgR mRNA expression is unaffected in NTera2-derived neurones by exposure to cytokines and neurotrophic factors
Previously, we showed that NTera2-N cells, a model of differentiated human neurones in culture, expressed mRNA coding for type 1 TNF receptor (TNFR1), type 1 IL-1 receptor (IL-1R1), FGF receptor-1 (FGFR-1), lowaffinity NGF receptor (LNGFR), tyrosine kinase receptor (trkB), GDNF receptor-a (GDNFRa), or the receptor tyrosine kinase (RET), suggesting that they are capable of responding to TNF-a, IL-1b, bFGF, BDNF and GDNF [34, 36, 38] . Therefore, Nogo and NgR mRNA expression was studied by Northern blot analysis in NTera2-N cells following exposure to these cytokines and neurotrophic factors. Nogo-A, Nogo-B, NgR and GAP-43 mRNA levels remained unaltered in NTera2-N cells after a 48-h treatment with 100 ng/ml of bFGF, BDNF, GDNF, TNF-a or IL-1b, or 1 mM of dbcAMP or 100 nM of PMA, when the levels of their expression were standardized against corresponding b-actin mRNA signals detected on the identical blots (Figure 4a-d, lanes  1-8) . These results indicate that Nogo and NgR mRNA expression is unaffected in NTera2-N cells by exposure to cytokines and neurotrophic factors which might be involved in inflammation-related axonal regeneration and neuronal survival in the CNS following injury.
Discussion
The present study has demonstrated that (i) various human neural and non-neural cell lines expressed constitutively Nogo-A and NgR mRNA; (ii) RA-induced neuronal differentiation up-regulated Nogo-A mRNA expression in NTera2 cells; and (iii) a panel of cytokines and neurotrophic factors failed to affect Nogo-A, Figure 2 . Nogo receptor mRNA expression in human neural and non-neural cell lines. Fifty ng of cDNA was amplified by PCR using the primer sets listed in Table 1 , specific for the human Nogo receptor (NgR) gene (a,b) or the human glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene (c). The amplified products separated on a 1.5% agarose gel were transferred onto a nylon membrane and hybridized with the NgR-specific internal oligonucleotide probe (b). Ethidium bromide staining of the gels is shown in (a,c), while (b) is a Southern blot of the gel corresponding to (a). Lanes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) represent the following human cells and tissues: (1) IMR-32 neuroblastoma, (2) SK-N-SH neuroblastoma, (3) U-373MG astrocytoma, (4) NTera2 teratocarcinoma maintained in the undifferentiated state (NTera2-U), (5) NTera2-derived differentiated neurones (NTera2-N), (6) HeLa cervical carcinoma, (7) HepG2 hepatoblastoma, (8) cultured skin fibroblasts (SF), (9) peripheral blood mononuclear cells (PBMC), (10) cerebrum processed for PCR including the RT step, (11) cerebrum processed for PCR omitting the RT step, (12) cerebellum, (13) peripheral nerve of the cauda equina and (14) skeletal muscle. The DNA size marker (bp) is shown on the left. Nogo, NgR and GAP-43 mRNA expression in NTera2-derived differentiated neurones after exposure to cytokines and neurotrophic factors. NTera2-N cells were incubated for 48 h in the serum-free culture medium containing bFGF, BDNF, GDNF, TNF-a, IL-1b, dbcAMP or PMA. Four mg of total RNA separated on a 1.5% agarose-6% formaldehyde gel was transferred onto a nylon membrane. It was then hybridized with the DIG-labelled DNA probe specific for the human NgR gene (b), followed by rehybridization with the DIG-labelled DNA probe specific for the sequence common among all three human Nogo transcripts (a) or the human GAP-43 gene (c), or with the human b-actin gene-specific RNA probe (d). Lanes (1-8) represent the following: (1) untreated, (2) 1 mM dbcAMP, (3) 100 nM PMA, (4) 100 ng/ml basic FGF (bFGF), (5) 100 ng/ml BDNF, (6) 100 ng/ml GDNF, (7) 100 ng/ml of TNF-a and (8) Nogo-B, NgR and GAP-43 mRNA expression in NTera2-derived differentiated neurones (NTera2-N). Previous studies have shown that both NI-35 and NI-250, the myelin-associated inhibitors of neurite outgrowth, are expressed almost exclusively on myelinforming oligodendrocytes [13, 41, 42] . In contrast, recent studies indicated that Nogo-A expression is detectable in subpopulations of neurones [14, 23] . Importantly, an in situ hybridization analysis showed that Nogo-A mRNA is expressed at high levels in motor neurones and sensory ganglia neurones in the adult human spinal cord [23] . The present study, using the more sensitive RT-PCR method, showed that human non-neural cells also express substantial levels of Nogo-A and NgR mRNA, suggesting that the biological roles of Nogo/NgR are not restricted to the nervous system. Supporting our view, NgR mRNA is found to be expressed in adult mouse heart and kidney tissues [16] . Nogo-C protein is identified in adult rat skeletal muscle and adipocytes [30] . A multivalent form of Amino-Nogo, composed of the N-terminal cytoplasmic domain of Nogo-A, inhibits the spreading of 3T3 embryonic mouse fibroblasts in culture [16] .
Our previous studies showed that the expression of a set of key regulators of neuronal function, including a-synuclein, ubiquitin C-terminal hydrolase-L1, amyloid precursor protein b-secretase and defender against apoptotic cell death-1, is up-regulated in NTera2 cells after induction of neuronal differentiation [36] [37] [38] [39] . The present study revealed that Nogo-A mRNA levels are also elevated substantially in NTera2-N cells, accompanied with an increased expression of GAP-43, the neurite growth-associated protein, suggesting that Nogo-A/NgR-mediated signals might play an active role in the achievement of human neuronal functions, possibly by operating in an autocrine or paracrine fashion. GAP-43 is a major constituent of the axonal growth cone, where it plays a central role in transducing growth cone guidance signals that regulate cytoskeletal organization in the nerve ending [5] . Previous studies have demonstrated that the increased production of NI-35/250 during CNS myelination is inversely correlated with regional GAP-43 expression [24, 25] . Unmyelinated or lightly myelinated areas, including the substantia gelatinosa of the spinal cord, the nucleus of the solitary tract and the septum, express high levels of GAP-43, whereas densely myelinated regions, such as most brainstem nuclei, the tegmentum and the inferior colliculus, exhibit much lower levels of GAP-43 [24] . When myelination in the rat spinal cord is suppressed by neonatal X-irradiation, the regional GAP-43 expression is up-regulated markedly, associated with an enhanced regenerative potential in situ [25] . Overexpression of GAP-43 in transgenic mice induces the spontaneous formation of new synapses and promotes neurite sprouting after injury [11] . The inhibitory activity of NI-35/NI-250 involves a retrograde downregulation of GAP-43 expression in adult rat Purkinje cells [49] . All of these observations suggest that Nogo acts as a principal suppressor of neuronal GAP-43 expression during CNS myelination. However, a coordinated up-regulation of Nogo-A and GAP-43 mRNA expression in NTera2-N cells observed in the present study suggests that Nogo-A/NgR-mediated signals might not be directly involved in the transcriptional regulation of GAP-43 gene expression in differentiated human neurones, at least under culture conditions devoid of myelin formation.
Because cytokines and neurotrophic factors play a key role in inflammation-related axonal regeneration, we tested the hypothesis that these factors might regulate the expression of Nogo and NgR genes in differentiated human neurones. However, the present study showed that Nogo-A, Nogo-B, NgR and GAP-43 mRNA levels were unaltered in NTera2-N cells by exposure to bFGF, BDNF, GDNF, TNF-a or IL-1b, despite expression of their specific receptors in these cells [34, 36, 38] . These observations do not suggest an active involvement of cytokine/growth factor-responsive transcriptional factors or elements in the regulation of Nogo and NgR gene expression in differentiated human neurones, although their promoter regions remain to be characterized. A recent study has shown that Nogo-A mRNA levels are unaltered in neurones and oligodendrocytes at the site surrounding the zone of injury in the adult rat spinal cord [23] . Because a selective blockade on the interaction between Nogo-A and NgR might provide a promising approach for promoting recovery after the CNS injury [10, 12, 47, 49, 50] , it would be of paramount importance to clarify the mechanisms involved in the regulation of Nogo and NgR gene expression in human neurones and glial cells. and the Naito Foundation, and from the Symposium on Catecholamine Neurological Disorders, Sumitomo Pharmaceutical Co., Japan.
